Abivax SA
PAR:ABVX
Abivax SA
Total Equity
Abivax SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Equity
-€48m
|
CAGR 3-Years
-291%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€150.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
€52.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Equity
$86.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-2%
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Equity
€57m
|
CAGR 3-Years
21%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Equity?
Total Equity
-48m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Total Equity amounts to -48m EUR.
What is Abivax SA's Total Equity growth rate?
Total Equity CAGR 5Y
-68%
The average annual Total Equity growth rates for Abivax SA have been -291% over the past three years , -68% over the past five years .
